JPH11512424A - 活性化合物投与用賦形剤として使用するためのマイクロエマルジョン - Google Patents
活性化合物投与用賦形剤として使用するためのマイクロエマルジョンInfo
- Publication number
- JPH11512424A JPH11512424A JP9511878A JP51187897A JPH11512424A JP H11512424 A JPH11512424 A JP H11512424A JP 9511878 A JP9511878 A JP 9511878A JP 51187897 A JP51187897 A JP 51187897A JP H11512424 A JPH11512424 A JP H11512424A
- Authority
- JP
- Japan
- Prior art keywords
- microemulsion
- polar phase
- surfactant
- carbon atoms
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004530 micro-emulsion Substances 0.000 title claims abstract description 76
- 150000001875 compounds Chemical class 0.000 title claims abstract description 32
- 239000000546 pharmaceutical excipient Substances 0.000 title claims abstract description 14
- 239000004094 surface-active agent Substances 0.000 claims abstract description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 28
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 4
- 239000000787 lecithin Substances 0.000 claims abstract description 4
- 229940067606 lecithin Drugs 0.000 claims abstract description 4
- 235000010445 lecithin Nutrition 0.000 claims abstract description 4
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 4
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 4
- 150000003408 sphingolipids Chemical class 0.000 claims abstract description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 19
- 150000004665 fatty acids Chemical class 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 16
- 239000000194 fatty acid Substances 0.000 claims description 16
- 229930195729 fatty acid Natural products 0.000 claims description 16
- -1 hydroxyethyl lactamide Chemical compound 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- 150000005690 diesters Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 239000003833 bile salt Substances 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 5
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 229940113115 polyethylene glycol 200 Drugs 0.000 claims description 4
- 239000008347 soybean phospholipid Substances 0.000 claims description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 3
- 229940114069 12-hydroxystearate Drugs 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 125000003158 alcohol group Chemical group 0.000 claims description 3
- 229940093761 bile salts Drugs 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000000561 anti-psychotic effect Effects 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 230000001085 cytostatic effect Effects 0.000 claims description 2
- 238000011067 equilibration Methods 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 150000002194 fatty esters Chemical class 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 229930182478 glucoside Natural products 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
- 229940075495 isopropyl palmitate Drugs 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 2
- 239000000612 proton pump inhibitor Substances 0.000 claims description 2
- 239000002461 renin inhibitor Substances 0.000 claims description 2
- 229940086526 renin-inhibitors Drugs 0.000 claims description 2
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 150000005691 triesters Chemical class 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000000474 Poliomyelitis Diseases 0.000 claims 1
- 239000004721 Polyphenylene oxide Substances 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940105132 myristate Drugs 0.000 claims 1
- 229920000570 polyether Polymers 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 150000003738 xylenes Chemical class 0.000 claims 1
- 239000003607 modifier Substances 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000007951 isotonicity adjuster Substances 0.000 abstract description 3
- 239000012071 phase Substances 0.000 description 19
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 15
- 238000002565 electrocardiography Methods 0.000 description 12
- 230000004872 arterial blood pressure Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 238000005191 phase separation Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 3
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229960003580 felodipine Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- RXXXUIOZOITBII-UHFFFAOYSA-N indeno[1,2-g]indole Chemical compound C1=C2C=CC=CC2=C2C1=C1N=CC=C1C=C2 RXXXUIOZOITBII-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- RSBHKNDSJJBCMN-UHFFFAOYSA-N 1-(1-hydroxyethyl)pyrrolidin-2-one Chemical compound CC(O)N1CCCC1=O RSBHKNDSJJBCMN-UHFFFAOYSA-N 0.000 description 1
- VBCKYDVWOPZOBA-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxymethyl)oxolane Chemical compound C1CCOC1COCC1CCCO1 VBCKYDVWOPZOBA-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101100136062 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) PE10 gene Proteins 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.- 水および場合により等張性状態にするための剤、および極性相の極性を調 整する1種またはそれ以上の成分(調整剤)を含有する極性相、 - 界面活性剤フイルム調整剤、 - 少なくとも1種の医薬的に許容し得る油状物からなる非極性相および - 全マイクロエマルジョンの15重量%までの、親油性界面活性剤と親水性界 面活性剤との混合物、ここで親油性界面活性剤はレシチン、スフィンゴ脂質およ びガラクト脂質からなる群より選択される、 を含有する、水中での溶解度が低い1種またはそれ以上の活性化合物を投与 するための賦形剤としての無毒性の水中油型または二連続性のマイクロエマルジ ョン。 2.極性相の極性を調整する成分が1種またはそれ以上の a)ポリエチレングリコール、すなわちポリエチレングリコール200、ポリエ チレングリコール300またはポリエチレングリコール400;プロピレングリコール ;グルコフロール;グリセロール;または1種またはそれ以上の b)ソルビトール;マンニトール;単糖類;二糖類;または1種またはそれ以 上の c)ジメチルアセトアミド;ソルケタール;メチルピロリドン;1−ヒドロキ シエチル−2−ピロリドンまたはヒドロキシエチルラクトアミド であることを特徴とする請求項1記載のマイクロエマルジョン。 3.極性相の極性を調整する成分が1種またはそれ以上の a)ポリエチレングリコール;プロピレングリコール;グルコフロール;グリ セロール;または1種またはそれ以上の b)ソルビトール;マンニトール;単糖類または二糖類 であることを特徴とする請求項2記載のマイクロエマルジョン。 4.極性相の極性を調整する成分がポリエチレングリコール400であることを特 徴とする請求項2または3に記載のマイクロエマルジョン。 5.等張性状態を得るための剤がNaClまたはグリセロールの溶液であることを特 徴とする請求項1記載のマイクロエマルジョン。 6.界面活性剤フイルム調整剤が2〜3個の炭素原子を有するアルコールである ことを特徴とする請求項1記載のマイクロエマルジョン。 7.界面活性剤フイルム調整剤がエタノールであることを特徴とする請求項6記 載のマイクロエマルジョン。 8.非極性相中の医薬的に許容し得る油状物が4〜18個の炭素原子を有するトリ グリセリド;4〜18個の炭素原子を有する脂肪酸を含有するプロピレングリコー ルのジエステル;1〜5個の炭素原子からなるアルコール部分または8〜22個の 炭素原子を有する脂肪酸部分を含有する脂肪酸のモノエステルまたはそれらの混 合物であることを特徴とする請求項1記載のマイクロエマルジョン。 9.非極性相中の医薬的に許容し得る油状物が、少なくとも70%の8〜10個の炭 素原子を有する脂肪酸を含有するトリグリセリド;少なくとも70%の8〜10個の 炭素原子を有する脂肪酸を含有するプロピレングリコールのジエステル;イソプ ロピルミリステート、イソプロピルパルミテートもしくはエチルオレエートのよ うなモノエステルまたはそれらの混合物であることを特徴とする請求項8記載の マイクロエマルジョン。 10.非極性相中の医薬的に許容し得る油状物が、少なくとも70%の8〜10 個の炭素原子を有する脂肪酸を含有するトリグリセリド;イソプロピルミリステ ートまたはそれらの混合物であることを特徴とする請求項9記載のマイクロエマ ルジョン。 11.親油性界面活性剤が、少なくとも90%のホスファチジルコリンからなる精製 ダイズレシチンであることを特徴とする請求項1記載のマイクロエマルジョン。 12.親水性界面活性剤が、エトキシル化ヒマシ油;エトキシル化脂肪エステル; スクロース脂肪エステル;ソルビトールまたはソルビタンおよびそれらのポリオ キシエチレン誘導体のモノエステル、ジエステルおよびトリエステル;アルキル グルコシドまたはアルキルポリグルコシド;エトキシル化モノヒドロキシステア リン酸または胆汁酸塩であることことを特徴とする請求項1記載のマイクロエマ ルジョン。 13.親油性界面活性剤がポリエチレングリコール(15)-12-ヒドロキシステアレー ト、アルキルマルトシド、胆汁酸塩またはそれらの混合物であることを特徴とす る請求項12記載のマイクロエマルジョン。 14.界面活性剤の量が、全マイクロエマルジョンの15重量%までであることを特 徴とする請求項1記載のマイクロエマルジョン。 15.界面活性剤の量が、全マイクロエマルジョンの4〜12重量%であることを特 徴とする請求項1記載のマイクロエマルジョン。 16.水中油型マイクロエマルジョンであることを特徴とする請求項1記載のマイ クロエマルジョン。 17.活性化合物が医薬であることを特徴とする請求項1記載のマイクロエマルジ ョン。 18.活性化合物がプロトンポンプ阻害剤、カルシウムチャンネル遮断剤、ベータ 遮断剤、麻酔薬、ステロイド、抗酸化剤、レニン阻害剤、アルカ ロイド、細胞増殖抑止剤、抗凝固剤、脂質調整剤、抗うつ剤、抗精神病薬、免疫 抑制剤、免疫調整剤、抗生物質および抗炎症剤であることを特徴とする請求項17 記載のマイクロエマルジョン。 19.各成分を特定の順序ではなく一緒に混合し、その混合物を典型的には1また は2日間放置して平衡状態にし、その際この平衡化操作は混合物を約40℃に温和 に加熱し、そして混合物を規則的な間隔で撹拌または振盪することにより短縮す ることができることを特徴とする請求項1記載のマイクロエマルジョンの調製方 法。 20.1種またはそれ以上の活性化合物の有効量をそのような活性化合物を必要と する宿主に投与するための請求項1〜18のいずれか1項に記載のマイクロエマル ジョンの使用。 21.1種またはそれ以上の活性化合物の有効量をそのような活性化合物を必要と する宿主に非経口投与するための請求項20記載のマイクロエマルジョンの使用。 22.1種またはそれ以上の活性化合物の有効量をそのような活性化合物を必要と する宿主に経口投与するための請求項20記載のマイクロエマルジョンの使用。 23.1種またはそれ以上の活性化合物の有効量をそのような活性化合物を必要と する宿主に経皮投与するための請求項20記載のマイクロエマルジョンの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9503143A SE9503143D0 (sv) | 1995-09-12 | 1995-09-12 | New preparation |
SE9503143-1 | 1995-09-12 | ||
PCT/SE1996/001097 WO1997009964A1 (en) | 1995-09-12 | 1996-09-04 | Microemulsions for use as vehicles for administration of active compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11512424A true JPH11512424A (ja) | 1999-10-26 |
JP4203123B2 JP4203123B2 (ja) | 2008-12-24 |
Family
ID=20399446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51187897A Expired - Fee Related JP4203123B2 (ja) | 1995-09-12 | 1996-09-04 | 活性化合物投与用賦形剤として使用するためのマイクロエマルジョン |
Country Status (27)
Country | Link |
---|---|
US (1) | US6602511B2 (ja) |
EP (1) | EP0850046B1 (ja) |
JP (1) | JP4203123B2 (ja) |
KR (1) | KR100448953B1 (ja) |
CN (1) | CN1160057C (ja) |
AT (1) | ATE228822T1 (ja) |
AU (1) | AU702366B2 (ja) |
BR (1) | BR9610089A (ja) |
CA (1) | CA2230730C (ja) |
CZ (1) | CZ64398A3 (ja) |
DE (1) | DE69625213T2 (ja) |
DK (1) | DK0850046T3 (ja) |
EE (1) | EE9800070A (ja) |
ES (1) | ES2186802T3 (ja) |
HU (1) | HUP9901215A3 (ja) |
IL (1) | IL123638A (ja) |
IS (1) | IS4675A (ja) |
MX (1) | MX9801755A (ja) |
NO (1) | NO326404B1 (ja) |
NZ (1) | NZ318530A (ja) |
PL (1) | PL325825A1 (ja) |
PT (1) | PT850046E (ja) |
RU (1) | RU2164134C2 (ja) |
SE (1) | SE9503143D0 (ja) |
SK (1) | SK282390B6 (ja) |
TR (1) | TR199800437T1 (ja) |
WO (1) | WO1997009964A1 (ja) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9503143D0 (sv) | 1995-09-12 | 1995-09-12 | Astra Ab | New preparation |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US7030155B2 (en) | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
EP2127642A3 (en) * | 1998-08-13 | 2010-02-24 | Cima Labs, Inc. | Microemulsions as solid dosage forms for oral administration |
DE19859427A1 (de) * | 1998-12-22 | 2000-06-29 | Beiersdorf Ag | Kosmetische oder pharmazeutische lecithinhaltige Gele oder niedrigviskose, lecithinhaltige O/W-Mikroemulsionen |
GB9912476D0 (en) | 1999-05-28 | 1999-07-28 | Novartis Ag | Organic compounds |
FR2795960B1 (fr) * | 1999-07-05 | 2001-10-19 | Sanofi Elf | Microemulsions stables pour l'administration d'acides gras a l'homme ou a l'animal, et utilisation de ces microemulsions |
KR100441167B1 (ko) * | 2001-12-27 | 2004-07-21 | 씨제이 주식회사 | 마이크로에멀젼 예비 농축액 조성물 |
AU2003219942A1 (en) * | 2002-03-01 | 2003-09-16 | Cesi Chemical, A Flotek Company | Composition and process for well cleaning |
DE10213955A1 (de) * | 2002-03-28 | 2003-10-09 | Beiersdorf Ag | Kosmetische oder pharmazeutische phospholipidhaltige, niedrigviskose (versprühbare) O/W-Emulsionen |
DE10213957A1 (de) * | 2002-03-28 | 2003-10-09 | Beiersdorf Ag | Vernetzte kosmetische oder pharmazeutische phospholipidhaltige Gele und Emulsionen auf der Basis von ethylenoxidhaltigen oder propylenoxidhaltigen Emulgatoren |
US7811594B2 (en) | 2002-03-28 | 2010-10-12 | Beiersdorf Ag | Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions |
US20050124705A1 (en) * | 2002-03-28 | 2005-06-09 | Beiersdorf Ag | Cosmetic or pharmaceutical, low-viscosity oil-in-water emulsions containing phospholipids |
ES2276110T3 (es) * | 2002-06-28 | 2007-06-16 | Speedel Pharma Ag | Formulacion farmaceutica que incluye un inhibidor de renina no peptidico y un tensioactivo. |
TWI348381B (en) * | 2002-12-27 | 2011-09-11 | Kao Corp | Skin cleansing composition |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
PE20050596A1 (es) * | 2003-12-19 | 2005-10-18 | Novartis Ag | Microemulsion que comprende un inhibidor renina |
EP1713444A4 (en) | 2004-02-13 | 2012-06-20 | Bioavailability Inc | MICROEMULSION PREPARATION OF HIGHLY CONCENTRATED PROPOFOL FOR APPLICATIONS IN ANESTHESIA |
US7727576B2 (en) * | 2004-04-16 | 2010-06-01 | Hewlett-Packard Development Company, L.P. | System and a method for producing layered oral dosage forms |
US20050232974A1 (en) * | 2004-04-19 | 2005-10-20 | Gore Makarand P | System and a method for pharmaceutical dosage preparation using jettable microemulsions |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US20060222692A1 (en) * | 2005-03-31 | 2006-10-05 | Fairfield Clinical Trials Llc | Method and compositions for transdermal administration of antimicrobial medications |
US11311477B2 (en) * | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
US10137083B2 (en) * | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
US9918934B2 (en) * | 2006-12-12 | 2018-03-20 | Edgar Joel Acosta-Zara | Linker-based lecithin microemulsion delivery vehicles |
EP1938801A1 (en) * | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
US20080199589A1 (en) * | 2007-02-20 | 2008-08-21 | Cargill, Incorporated | Lipid Microemulsions |
EP1985298A1 (en) * | 2007-04-24 | 2008-10-29 | Azad Pharma AG | Ophtalmic oil-in-water emulsions containing prostaglandins |
US9222013B1 (en) | 2008-11-13 | 2015-12-29 | Cesi Chemical, Inc. | Water-in-oil microemulsions for oilfield applications |
WO2011019911A1 (en) | 2009-08-14 | 2011-02-17 | Opko Health, Inc. | Intravenous formulations of neurokinin-1 antagonists |
JP4834775B2 (ja) | 2010-03-04 | 2011-12-14 | 株式会社 資生堂 | 日焼け止め用組成物 |
NL2005365C2 (en) * | 2010-09-17 | 2012-03-20 | Univ Delft Tech | Carbon nanostructures and networks produced by chemical vapor deposition. |
DK2838970T3 (en) | 2012-04-15 | 2017-03-20 | Flotek Chemistry Llc | Density formulations for foam filling |
US9200192B2 (en) | 2012-05-08 | 2015-12-01 | Cesi Chemical, Inc. | Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons |
US11407930B2 (en) | 2012-05-08 | 2022-08-09 | Flotek Chemistry, Llc | Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons |
US9801819B2 (en) * | 2012-06-28 | 2017-10-31 | Johnson & Johnson Consumer Inc. | Racecadotril compositions |
RU2632441C2 (ru) * | 2012-06-28 | 2017-10-04 | МакНЕЙЛ-ППС, ИНК. | Липидные композиции рацекадотрила |
US10577531B2 (en) | 2013-03-14 | 2020-03-03 | Flotek Chemistry, Llc | Polymers and emulsions for use in oil and/or gas wells |
US9464223B2 (en) | 2013-03-14 | 2016-10-11 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
US10287483B2 (en) | 2013-03-14 | 2019-05-14 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells comprising a terpene alcohol |
US10000693B2 (en) | 2013-03-14 | 2018-06-19 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
US10717919B2 (en) | 2013-03-14 | 2020-07-21 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
US10421707B2 (en) | 2013-03-14 | 2019-09-24 | Flotek Chemistry, Llc | Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells |
US9884988B2 (en) | 2013-03-14 | 2018-02-06 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
US9321955B2 (en) | 2013-06-14 | 2016-04-26 | Flotek Chemistry, Llc | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
US10053619B2 (en) | 2013-03-14 | 2018-08-21 | Flotek Chemistry, Llc | Siloxane surfactant additives for oil and gas applications |
US11180690B2 (en) | 2013-03-14 | 2021-11-23 | Flotek Chemistry, Llc | Diluted microemulsions with low surface tensions |
US11254856B2 (en) | 2013-03-14 | 2022-02-22 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
US10941106B2 (en) | 2013-03-14 | 2021-03-09 | Flotek Chemistry, Llc | Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells |
US10590332B2 (en) | 2013-03-14 | 2020-03-17 | Flotek Chemistry, Llc | Siloxane surfactant additives for oil and gas applications |
US9068108B2 (en) | 2013-03-14 | 2015-06-30 | Cesi Chemical, Inc. | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
US9428683B2 (en) | 2013-03-14 | 2016-08-30 | Flotek Chemistry, Llc | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
US9868893B2 (en) | 2013-03-14 | 2018-01-16 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
US9890625B2 (en) | 2014-02-28 | 2018-02-13 | Eclipse Ior Services, Llc | Systems and methods for the treatment of oil and/or gas wells with an obstruction material |
US9890624B2 (en) | 2014-02-28 | 2018-02-13 | Eclipse Ior Services, Llc | Systems and methods for the treatment of oil and/or gas wells with a polymeric material |
CA2891278C (en) | 2014-05-14 | 2018-11-06 | Cesi Chemical, Inc. | Methods and compositions for use in oil and / or gas wells |
CA2898770C (en) | 2014-07-28 | 2019-05-21 | Cesi Chemical, Inc. | Methods and compositions related to gelled layers in oil and/or gas wells |
JP2017181387A (ja) * | 2016-03-31 | 2017-10-05 | 株式会社ポーラファルマ | 医薬組成物の形成する膜の評価方法 |
US10934472B2 (en) | 2017-08-18 | 2021-03-02 | Flotek Chemistry, Llc | Compositions comprising non-halogenated solvents for use in oil and/or gas wells and related methods |
US11053433B2 (en) | 2017-12-01 | 2021-07-06 | Flotek Chemistry, Llc | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
CN109401745B (zh) * | 2018-11-21 | 2021-03-12 | 西南石油大学 | 一种自适应流度控制体系及其在高温高盐油藏的应用 |
US11104843B2 (en) | 2019-10-10 | 2021-08-31 | Flotek Chemistry, Llc | Well treatment compositions and methods comprising certain microemulsions and certain clay control additives exhibiting synergistic effect of enhancing clay swelling protection and persistency |
US11512243B2 (en) | 2020-10-23 | 2022-11-29 | Flotek Chemistry, Llc | Microemulsions comprising an alkyl propoxylated sulfate surfactant, and related methods |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2553666B1 (fr) | 1983-10-21 | 1986-10-31 | Correia Gabriel | Dispositif permettant de sentir individuellement odeurs et parfums en liaison avec des images et des sons |
DE3406497A1 (de) | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung |
IL78929A0 (en) | 1985-07-29 | 1986-09-30 | Abbott Lab | Microemulsion compositions for parenteral administration |
FR2628632B1 (fr) | 1988-03-18 | 1992-04-03 | Gattefosse Ets Sa | Microemulsions a usage cosmetique ou pharmaceutique |
US5364632A (en) * | 1989-04-05 | 1994-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
CA2013755C (en) | 1989-04-05 | 1993-11-30 | Simon Benita | Medicinal emulsions |
ES2136620T3 (es) | 1991-04-19 | 1999-12-01 | Lds Technologies Inc | Formulaciones de microemulsiones convertibles. |
DK0597007T3 (da) | 1991-07-26 | 1996-11-18 | Smithkline Beecham Corp | V/O mikroemulsioner |
FR2709666B1 (fr) | 1993-09-07 | 1995-10-13 | Oreal | Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire. |
DE4338046A1 (de) * | 1993-11-08 | 1995-05-11 | Dietl Hans | Fettlösliche Arzneimittel erhaltende flüssige pharmazeutische Zubereitung zur oralen Anwendung |
FR2730932B1 (fr) | 1995-02-27 | 1997-04-04 | Oreal | Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie |
SE9503143D0 (sv) | 1995-09-12 | 1995-09-12 | Astra Ab | New preparation |
-
1995
- 1995-09-12 SE SE9503143A patent/SE9503143D0/xx unknown
-
1996
- 1996-09-04 DE DE69625213T patent/DE69625213T2/de not_active Expired - Lifetime
- 1996-09-04 IL IL12363896A patent/IL123638A/en not_active IP Right Cessation
- 1996-09-04 SK SK283-98A patent/SK282390B6/sk unknown
- 1996-09-04 AT AT96931319T patent/ATE228822T1/de active
- 1996-09-04 CA CA002230730A patent/CA2230730C/en not_active Expired - Fee Related
- 1996-09-04 HU HU9901215A patent/HUP9901215A3/hu unknown
- 1996-09-04 NZ NZ318530A patent/NZ318530A/en not_active IP Right Cessation
- 1996-09-04 RU RU98106482/14A patent/RU2164134C2/ru active
- 1996-09-04 TR TR1998/00437T patent/TR199800437T1/xx unknown
- 1996-09-04 BR BR9610089A patent/BR9610089A/pt not_active IP Right Cessation
- 1996-09-04 DK DK96931319T patent/DK0850046T3/da active
- 1996-09-04 CN CNB961981377A patent/CN1160057C/zh not_active Expired - Fee Related
- 1996-09-04 KR KR10-1998-0701818A patent/KR100448953B1/ko not_active IP Right Cessation
- 1996-09-04 JP JP51187897A patent/JP4203123B2/ja not_active Expired - Fee Related
- 1996-09-04 CZ CZ98643A patent/CZ64398A3/cs unknown
- 1996-09-04 WO PCT/SE1996/001097 patent/WO1997009964A1/en active IP Right Grant
- 1996-09-04 ES ES96931319T patent/ES2186802T3/es not_active Expired - Lifetime
- 1996-09-04 US US08/718,485 patent/US6602511B2/en not_active Expired - Fee Related
- 1996-09-04 PT PT96931319T patent/PT850046E/pt unknown
- 1996-09-04 EE EE9800070A patent/EE9800070A/xx unknown
- 1996-09-04 AU AU70037/96A patent/AU702366B2/en not_active Ceased
- 1996-09-04 EP EP96931319A patent/EP0850046B1/en not_active Expired - Lifetime
- 1996-09-04 PL PL96325825A patent/PL325825A1/xx unknown
-
1998
- 1998-02-25 IS IS4675A patent/IS4675A/is unknown
- 1998-03-05 MX MX9801755A patent/MX9801755A/es not_active IP Right Cessation
- 1998-03-09 NO NO19981021A patent/NO326404B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4203123B2 (ja) | 活性化合物投与用賦形剤として使用するためのマイクロエマルジョン | |
Von Corswant et al. | Triglyceride-based microemulsion for intravenous administration of sparingly soluble substances | |
KR100345627B1 (ko) | 단기간작용하는디히드로피리딘을함유하는약제학적유제및그의제조방법 | |
ES2199338T3 (es) | Composiciones farmaceuticas en emulsion, que contienen (3'-desoxi-3'-oxo-mebmt)1-(val)2-ciclosporin. | |
EP0556394B1 (en) | Lyophilized preparation and production thereof | |
JP2008231117A (ja) | キサンチン誘導体含有脂肪乳剤 | |
JP2006508104A (ja) | 難溶性風邪薬の経口投与用マイクロエマルション濃縮液及びその製造方法 | |
JPS62270521A (ja) | フルルビプロフエン眼投与製剤 | |
EP0233849B1 (en) | Composition of pregnanolole comprising a stable oil-in-water emulsion | |
JPH0723303B2 (ja) | 難溶性薬物含有マイクロエマルシヨン製剤 | |
JP3132085B2 (ja) | 脂肪乳剤 | |
JP2653245B2 (ja) | 脂肪乳剤 | |
EP0558750A1 (en) | Dispersion preparation | |
JP3074732B2 (ja) | 脂肪乳剤 | |
JPH0138767B2 (ja) | ||
TWI819756B (zh) | 包含塞納布啡的藥物組合物 | |
JP2626247B2 (ja) | 凍結乾燥製剤及び製法 | |
RU2097025C1 (ru) | Лиофилизированный препарат жировой эмульсии и способ его получения | |
WO2002009670A1 (en) | Liquid or semi-solid pharmaceutical excipient and pharmaceutical composition comprising the same | |
JPH0489430A (ja) | 低血圧維持剤 | |
JPH0816058B2 (ja) | トルナフテ−ト含有マイクロエマルシヨン製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070814 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071108 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080325 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080527 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080812 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080930 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081010 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111017 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |